# SPINRAZA Clinical Trial Data
Keywords: SPINRAZA, SMA, 5q SMA, pre-symptomatic infants, respiratory intervention, motor milestones, clinical trials

> This page provides detailed information on the clinical trial data for SPINRAZA, focusing on its use in pre-symptomatic infants diagnosed with Spinal Muscular Atrophy (SMA). It highlights key findings, study design, and long-term outcomes.

## Details
- [Overview](#): SPINRAZA is discussed in the context of its effectiveness in treating pre-symptomatic infants with SMA.
- [Study Design](#): The NURTURE study, a Phase II open-label trial, evaluated SPINRAZA in infants likely to develop SMA Type I or II, with over 8 years of follow-up data.
- [Survival](#): 100% of pre-symptomatic patients treated with SPINRAZA were alive and did not require permanent ventilation.
- [Motor Milestones](#): Details the motor milestone achievements of patients treated early with SPINRAZA.
- [Disease Activity](#): Analysis of disease activity in patients treated with SPINRAZA.
- [Safety Outcomes](#): Safety outcomes and adverse events associated with SPINRAZA treatment are discussed.
- [References](#): Lists sources and studies cited, including the NURTURE study and other relevant publications.